pantoprazole has been researched along with Hemorrhage, Peptic Ulcer in 56 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5) with rheumatoid arthritis or osteoarthritis, requiring chronic intake of NSAIDs (at least 8 weeks prior to the start of the study), were randomised and enrolled to receive either 40 mg pantoprazole (n=70) or placebo (n=34) once daily, for 12 weeks." | 5.09 | Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study. ( Bianchi Porro, G; Imbesi, V; Lazzaroni, M; Montrone, F; Santagada, T, 2000) |
| "The aim of this study is to assess the prevalence of peptic ulcer rebleeding by comparing patients who received omeprazole versus pantoprazole i." | 3.76 | [Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors]. ( de Sousa, M; Garrido, A; Iborra, MI; Saperas, E, 2010) |
| "We present the case of a patient taking aspirin and etoricoxib who was admitted with upper digestive haemorrhage due to duodenal ulcer." | 3.75 | Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors. ( Soares, J, 2009) |
| "The optimal dosage of intravenous proton pump inhibitors (PPIs) for the prevention of peptic ulcer rebleeding remains unclear." | 2.77 | Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers. ( Chen, CC; Fang, YJ; Han, ML; Hsu, SJ; Hu, FC; Lee, JY; Lin, JT; Lin, TL; Liou, JM; Tseng, PH; Wang, HP; Wu, MS, 2012) |
| "The optimal dosage of proton pump inhibitor in bleeding peptic ulcers remains controversial." | 2.75 | A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding. ( Cheng, YC; Chiang, MF; Hsu, WL; Hsu, YC; Lin, HJ; Perng, CL; Wang, CS; Wu, HT; Yang, TH, 2010) |
| "omeprazole was 6." | 2.74 | Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Shah, AH; Sodhi, JS; U-Saif, R; Yatoo, GN; Zargar, SA, 2009) |
| "Bleeding recurrence: group S 14 patients (17%) versus group P 4 (5%) (P=0." | 2.73 | High-dose pantoprazole continuous infusion is superior to somatostatin after endoscopic hemostasis in patients with peptic ulcer bleeding. ( Galeas, T; Lappas, C; Moussia, M; Potamianos, S; Tsianos, G; Tsibouris, P; Zintzaras, E, 2007) |
| " Data collected included demographics, indication and dosing of pantoprazole, admitting team (surgery vs." | 1.35 | Intravenous pantoprazole utilization in a level 1 trauma center. ( Edelman, DA; Patel, KR; Tyburski, JG; Zimmerman, LG, 2008) |
| " The setting-specific appropriateness of the IV PPI indication and dosing regimen was determined." | 1.33 | Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. ( Bates, D; Kaplan, GG; McDonald, D; Panaccione, R; Romagnuolo, J, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (60.71) | 29.6817 |
| 2010's | 21 (37.50) | 24.3611 |
| 2020's | 1 (1.79) | 2.80 |
| Authors | Studies |
|---|---|
| Kanjee, Z | 1 |
| Asombang, AW | 1 |
| Berzin, TM | 1 |
| B Burns, R | 1 |
| Sgourakis, G | 1 |
| Chatzidakis, G | 1 |
| Poulou, A | 1 |
| Malliou, P | 1 |
| Argyropoulos, T | 1 |
| Ravanis, G | 1 |
| Vagia, A | 1 |
| Kpogho, I | 1 |
| Briki, A | 1 |
| Tsuruhara, H | 1 |
| Stankovičová, T | 1 |
| Rattanasupar, A | 1 |
| Sengmanee, S | 1 |
| Quenot, JP | 1 |
| Dargent, A | 1 |
| Barkun, A | 1 |
| Bardou, M | 2 |
| Taş, A | 1 |
| Yang, SC | 1 |
| Chen, JC | 1 |
| Tai, WC | 2 |
| Wu, CK | 1 |
| Lee, CH | 1 |
| Wu, KL | 2 |
| Chiu, YC | 2 |
| Wang, JH | 1 |
| Lu, SN | 1 |
| Chuah, SK | 2 |
| Lanas, A | 2 |
| Carrera-Lasfuentes, P | 1 |
| García-Rodríguez, LA | 2 |
| García, S | 2 |
| Arroyo-Villarino, MT | 2 |
| Ponce, J | 2 |
| Bujanda, L | 2 |
| Calleja, JL | 2 |
| Polo-Tomas, M | 2 |
| Calvet, X | 2 |
| Feu, F | 2 |
| Perez-Aisa, A | 2 |
| Lenz, K | 1 |
| Buder, R | 1 |
| Firlinger, F | 1 |
| Lohr, G | 1 |
| Voglmayr, M | 1 |
| Ljubičić, N | 1 |
| Pavić, T | 1 |
| Budimir, I | 1 |
| Puljiz, Ž | 1 |
| Bišćanin, A | 1 |
| Bratanić, A | 1 |
| Nikolić, M | 1 |
| Hrabar, D | 1 |
| Troskot, B | 1 |
| Chao, HC | 1 |
| Yu, WL | 1 |
| Lwin, AA | 1 |
| Lin, HJ | 2 |
| Tsai, JJ | 1 |
| Yüksel, I | 1 |
| Ataseven, H | 1 |
| Köklü, S | 1 |
| Ertuğrul, I | 1 |
| Başar, O | 1 |
| Odemiş, B | 1 |
| Ibiş, M | 1 |
| Saşmaz, N | 1 |
| Sahin, B | 1 |
| Garrido, A | 2 |
| Giráldez, A | 1 |
| Trigo, C | 1 |
| Leo, E | 1 |
| Guil, A | 1 |
| Márquez, JL | 1 |
| van Rensburg, C | 1 |
| Barkun, AN | 1 |
| Racz, I | 1 |
| Fedorak, R | 1 |
| Bornman, PC | 1 |
| Beglinger, C | 1 |
| Balanzó, J | 1 |
| Devière, J | 1 |
| Kupcinskas, L | 1 |
| Luehmann, R | 1 |
| Doerfler, H | 1 |
| Schäfer-Preuss, S | 1 |
| Wang, J | 1 |
| Yang, K | 1 |
| Ma, B | 1 |
| Tian, J | 1 |
| Liu, Y | 1 |
| Bai, Z | 1 |
| Jiang, L | 1 |
| Sun, S | 1 |
| Li, J | 1 |
| Liu, R | 1 |
| Hao, X | 1 |
| He, X | 1 |
| Tan, VP | 1 |
| Wong, BC | 1 |
| Javid, G | 2 |
| Zargar, SA | 2 |
| U-Saif, R | 1 |
| Khan, BA | 2 |
| Yatoo, GN | 1 |
| Shah, AH | 2 |
| Gulzar, GM | 2 |
| Sodhi, JS | 2 |
| Khan, MA | 2 |
| Choi, KD | 1 |
| Kim, N | 1 |
| Jang, IJ | 1 |
| Park, YS | 1 |
| Cho, JY | 1 |
| Kim, JR | 1 |
| Shin, JM | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Banerjee, R | 1 |
| Reddy, DN | 1 |
| Guda, NM | 2 |
| Kalpala, R | 1 |
| Mahurkar, S | 1 |
| Darisetty, S | 1 |
| Rao, GV | 1 |
| Silva, AP | 1 |
| Soares, J | 1 |
| Chan, FK | 1 |
| Fein, F | 1 |
| Weber, A | 1 |
| Koch, S | 1 |
| Festou, N | 1 |
| Dupont-Gossard, AC | 1 |
| Cervoni, JP | 1 |
| Monnet, E | 1 |
| Carbonnel, F | 1 |
| Lin, PC | 1 |
| Chang, CH | 1 |
| Hsu, PI | 2 |
| Tseng, PL | 1 |
| Huang, YB | 1 |
| Iborra, MI | 1 |
| Saperas, E | 1 |
| de Sousa, M | 1 |
| Hsu, YC | 1 |
| Perng, CL | 1 |
| Yang, TH | 1 |
| Wang, CS | 1 |
| Hsu, WL | 1 |
| Wu, HT | 1 |
| Cheng, YC | 1 |
| Chiang, MF | 1 |
| Miranda, WR | 1 |
| Smith, JM | 1 |
| Burton, MC | 1 |
| Chen, CC | 1 |
| Lee, JY | 1 |
| Fang, YJ | 1 |
| Hsu, SJ | 1 |
| Han, ML | 1 |
| Tseng, PH | 1 |
| Liou, JM | 1 |
| Hu, FC | 1 |
| Lin, TL | 1 |
| Wu, MS | 1 |
| Wang, HP | 1 |
| Lin, JT | 1 |
| Liang, CM | 1 |
| Lee, JH | 1 |
| Kuo, YH | 1 |
| Chou, YP | 1 |
| Hu, ML | 1 |
| Chiu, KW | 1 |
| Hu, TH | 1 |
| Yamada, S | 1 |
| Wongwanakul, P | 1 |
| Gashi, Z | 1 |
| Joksimovic, N | 1 |
| Dragusha, G | 1 |
| Bakalli, A | 1 |
| Sung, JJ | 1 |
| Wu, XP | 1 |
| He, JR | 1 |
| Wang, CL | 1 |
| Ling, QH | 1 |
| Hiramoto, JS | 1 |
| Terdiman, JP | 1 |
| Norton, JA | 1 |
| Pais, SA | 1 |
| Yang, R | 1 |
| Bustamante Baléna, M | 1 |
| Ponce García, J | 1 |
| Yap, LM | 1 |
| Hagan, S | 1 |
| Craig, A | 1 |
| Hebbard, GG | 1 |
| Young, GP | 1 |
| Bampton, PA | 1 |
| Noonan, M | 1 |
| Kreiner, MJ | 1 |
| Partington, S | 1 |
| Vakil, N | 1 |
| Martin, RA | 1 |
| Lo, GH | 1 |
| Lo, CC | 1 |
| Lin, CK | 1 |
| Chan, HH | 1 |
| Wu, CJ | 1 |
| Shie, CB | 1 |
| Tsai, PM | 1 |
| Wu, DC | 1 |
| Wang, WM | 1 |
| Lai, KH | 1 |
| Enns, R | 2 |
| Avgerinos, A | 1 |
| Sgouros, S | 1 |
| Viazis, N | 1 |
| Vlachogiannakos, J | 1 |
| Papaxoinis, K | 1 |
| Bergele, C | 1 |
| Sklavos, P | 1 |
| Raptis, SA | 1 |
| Andrews, CN | 1 |
| Levy, A | 1 |
| Fishman, M | 1 |
| Hahn, M | 1 |
| Atkinson, K | 1 |
| Kwan, P | 1 |
| Kaplan, GG | 1 |
| Bates, D | 1 |
| McDonald, D | 1 |
| Panaccione, R | 1 |
| Romagnuolo, J | 1 |
| Armstrong, D | 1 |
| Yattoo, GN | 1 |
| Mujeeb, SA | 1 |
| Shah, NA | 1 |
| Shafi, HM | 1 |
| Jensen, DM | 1 |
| Pace, SC | 1 |
| Soffer, E | 1 |
| Comer, GM | 1 |
| Tsibouris, P | 1 |
| Zintzaras, E | 1 |
| Lappas, C | 1 |
| Moussia, M | 1 |
| Tsianos, G | 1 |
| Galeas, T | 1 |
| Potamianos, S | 1 |
| Hung, WK | 1 |
| Li, VK | 1 |
| Chung, CK | 1 |
| Ying, MW | 1 |
| Loo, CK | 1 |
| Liu, CK | 1 |
| Lam, BY | 1 |
| Chan, MC | 1 |
| Edelman, DA | 1 |
| Patel, KR | 1 |
| Tyburski, JG | 1 |
| Zimmerman, LG | 1 |
| Ojiako, K | 1 |
| Shingala, H | 1 |
| Schorr, C | 1 |
| Gerber, DR | 1 |
| Carlson, RW | 1 |
| Baker, L | 1 |
| Andhavarapu, S | 1 |
| Bustamante, M | 1 |
| Stollman, N | 1 |
| Bianchi Porro, G | 1 |
| Lazzaroni, M | 1 |
| Imbesi, V | 1 |
| Montrone, F | 1 |
| Santagada, T | 1 |
| Bohle, W | 1 |
| Zoller, WG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled[NCT03098537] | 500 participants (Anticipated) | Interventional | 2016-08-01 | Recruiting | |||
| High Dose Versus Standard Dose Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Combined Endoscopic Hemostasis: A Prospective Randomized Comparative Study[NCT00709046] | 150 participants (Anticipated) | Interventional | 2008-01-31 | Recruiting | |||
| Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery[NCT00839488] | Phase 4 | 6 participants (Actual) | Interventional | 2008-04-30 | Terminated (stopped due to the chief of GS left the hopsital and the successor did't want to keep on this study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for pantoprazole and Hemorrhage, Peptic Ulcer
| Article | Year |
|---|---|
High-dose vs. Low-dose Proton Pump Inhibitors post-endoscopic hemostasis in patients with bleeding peptic ulcer. A meta-analysis and meta-regression analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Dose-Response Relationship, Drug; Female; Hemostasis, | 2018 |
Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Blood Transfusion; Chemotherapy, Adjuvan | 2009 |
The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cimetidine; Critical Care; Histamine H2 Antagonists; Humans | 2010 |
Evidence-based analysis: postoperative gastric bleeding: etiology and prevention.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analysis; D | 2003 |
Diagnostic and therapeutic options in the management of nonvariceal upper gastrointestinal bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Diathermy; Endoscopy, Ga | 2003 |
[Antisecretor treatment of digestive hemorrhage associated to peptic ulcer: an approximation to the available evidence].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
Intravenous proton pump inhibitor therapy: a rationale for use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2005 |
The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; Humans; | 2000 |
[Proton pump inhibitors in acute ulcer bleeding--what is evident?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Gastrointesti | 2000 |
18 trials available for pantoprazole and Hemorrhage, Peptic Ulcer
| Article | Year |
|---|---|
Comparison of High Dose and Standard Dose Proton Pump Inhibitor before Endoscopy in Patients with Non-Portal Hypertension Bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Dose-Response Relationship, Dr | 2016 |
Intermittent versus continuous pantoprazole infusion in peptic ulcer bleeding: a prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Duodenal | 2008 |
[Intravenous proton-pump inhibitor for acute peptic ulcer bleeding--is profound acid suppression beneficial to reduce the risk of rebleeding?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Female; Humans; Injections, Intravenous; Mal | 2008 |
Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Double-Blind Me | 2009 |
Comparison of p.o. or i.v. proton pump inhibitors on 72-h intragastric pH in bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Drug Administratio | 2009 |
Optimal dose of intravenous pantoprazole in patients with peptic ulcer bleeding requiring endoscopic hemostasis in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylas | 2009 |
Oral buffered esomeprazole is superior to i.v. pantoprazole for rapid rise of intragastric pH: a wireless pH metry analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Buffers; Chemistry, Pharmaceut | 2010 |
A randomized controlled trial comparing two different dosages of infusional pantoprazole in peptic ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Female; Humans; Infusions, Intravenous; | 2010 |
Randomised clinical trial: high-dose vs. standard-dose proton pump inhibitors for the prevention of recurrent haemorrhage after combined endoscopic haemostasis of bleeding peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; | 2012 |
Randomized controlled trial of high dose bolus versus continuous intravenous infusion pantoprazole as an adjunct therapy to therapeutic endoscopy in massive bleeding peptic ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; End | 2012 |
The efficacy of PPI after endoscopic hemostasis in patients with bleeding peptic ulcer and role of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Double-Blind Method; Female; Helicobacte | 2012 |
Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2004 |
Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: a prospective, randomized, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Fem | 2005 |
Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Chemotherapy, Adjuvant; | 2006 |
Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a U.S. multicenter randomized, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2006 |
High-dose pantoprazole continuous infusion is superior to somatostatin after endoscopic hemostasis in patients with peptic ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Double-Blind Method; Female; Gastr | 2007 |
Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Blood Transfusion; Female; Gastric Acidi | 2007 |
Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: a prospective, placebo-controlled, double-blind, parallel-group study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti- | 2000 |
29 other studies available for pantoprazole and Hemorrhage, Peptic Ulcer
| Article | Year |
|---|---|
How Would You Manage This Patient With Nonvariceal Upper Gastrointestinal Bleeding? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Topics: Aged; Blood Transfusion; Endoscopy, Gastrointestinal; Female; Humans; Pantoprazole; Peptic Ulcer Hem | 2021 |
Prophylaxis for stress related gastrointestinal bleeding in the ICU: Should we adjust to each patient's individual risk?
Topics: Anti-Ulcer Agents; Critical Care; Gastrointestinal Hemorrhage; Humans; Meta-Analysis as Topic; Panto | 2019 |
Thrombocytopenia as a side effect of pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Duodenal Ulcer; Humans; Male; | 2013 |
The influential roles of antibiotics prophylaxis in cirrhotic patients with peptic ulcer bleeding after initial endoscopic treatments.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibiotic | 2014 |
Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Intravenous; Administration, Oral; Adult; A | 2014 |
Effect of proton pump inhibitors on gastric pH in patients exposed to severe stress.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastric Acid; Gastric Acidity Determination; | 2015 |
North vs south differences in acute peptic ulcer hemorrhage in Croatia: hospitalization incidence trends, clinical features, and 30-day case fatality.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Administration, Oral; Age Distribution; Aged | 2014 |
Cytomegalovirus-infected duodenal ulcer with severe recurrent bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus In | 2016 |
Famotidine versus pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Illness; Famotidine; Histamine H2 Antagonists; Hum | 2008 |
Skeptical that pantoprazole dose can prevent bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Histamine H2 Antagonists; Hu | 2008 |
Management of acute peptic ulcers: how ethnicity, different proton pump inhibitors and mechanism of delivery alter the equation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Asian People; Drug Administration Sch | 2009 |
Recurrent duodenal ulcer due to nonsteroidal anti-inflammatories following the suspension of antiulcer medication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2009 |
Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2009 |
Immediate-release oral proton pump inhibitors: Panacea or a flash in the pan?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Buffers; Chemistry, Pharmaceutical; D | 2010 |
The prognosis of patients having received optimal therapy for nonvariceal upper gastrointestinal bleeding might be worse in daily practice than in randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Aged, 80 and over; Chi-S | 2010 |
[Prevalence of rebleeding from peptic ulcer in patients treated with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Costs; Female; Health Resources; Hospital Costs; | 2010 |
33-year-old woman with epigastric pain and hematemesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Diagnosis, Differential; Eosinoph | 2012 |
Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Case-Control Studies; Chi-Square Distribution; Creati | 2012 |
Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Confidence Intervals; Esomeprazole; Female; Hematemes | 2013 |
[Effect of pantoprazole on non-variceal bleeding].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Duodenal Ulcer; F | 2000 |
An audit of argon plasma coagulation, epinephrine injection, and proton-pump infusion therapy in the management of bleeding peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cohort Studies; Epinephr | 2004 |
Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2004 |
Utility of proton pump inhibitors in the treatment of gastrointestinal hemorrhage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Connecticut; Cost-Benefit Analysis; Enzyme | 2004 |
Less acid + less bleeding = better outcomes and more money!
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic | 2004 |
Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: a multicentre comparative study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Gastroi | 2005 |
Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Cost-Benefit Analy | 2005 |
Intravenous pantoprazole utilization in a level 1 trauma center.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Female; Humans; Injections, Intravenous; | 2008 |
Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Famotidine; Histamine H2 Antagonists; Humans; Middle | 2008 |
Bleeding in the upper part of the gastrointestinal tract due to stress ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Famotidine; Histamine H2 Antagonists; Humans; Pantoprazole; | 2008 |